Global Decentralized Clinical Trials Market Size/Share Worth USD 38.3 Billion by 2035 at a 14.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global decentralized clinical trials market is projected to grow from USD 9.9 billion in 2025 to USD 38.3 billion by 2035, at a CAGR of 14.5%. Growth is driven by digital health technologies, remote patient engagement, and ecosystem expansion involving CROs and platform vendors. Oncology represents the largest therapeutic segment at 45% market share, while pharmaceutical and biotech sponsors lead end-user adoption at 55% market share. North America currently dominates, while Asia-Pacific shows the fastest growth.

06/22/2026, 3:30 PM • GlobeNewswire

Clinical Trial Data Visualization Research Report 2026: $1.82 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

The clinical trial data visualization market is projected to grow from $0.89 billion in 2025 to $1.82 billion by 2030 at a CAGR of 15.4%, driven by increasing adoption of AI-powered solutions, cloud-based platforms, and decentralized trials. Major players include ICON plc, Oracle Corporation, and IQVIA Inc., with Asia-Pacific emerging as the fastest-growing region.

04/24/2026, 5:53 AM • GlobeNewswire

eCOA, eSource and Clinical Trials Research Report 2026: $81.46 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

The eCOA, eSource, and clinical trials market is projected to grow from $51.15 billion in 2025 to $81.46 billion by 2030 at a 9.8% CAGR, driven by AI adoption, decentralized trial models, and digital transformation. Key growth factors include regulatory acceptance of electronic records, cloud-based systems, and real-time data capture. Despite tariff challenges, regional software development is strengthening market resilience.

04/24/2026, 4:51 AM • GlobeNewswire

ICLR SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

ICON Public Limited Company's Audit Committee is investigating accounting practices and internal controls related to revenue recognition from fiscal years 2023-2025. The company disclosed material weaknesses in internal controls, delayed financial results, and withdrew 2025 guidance. ICON shares fell approximately 40% on the announcement, declining from $133.14 to $80.08 per share on February 12, 2026.

02/19/2026, 8:00 PM • GlobeNewswire

FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer

The FDA granted Breakthrough Therapy Designation to Johnson & Johnson's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for treating advanced, HPV-unrelated head and neck squamous cell carcinoma in adults. The drug is being evaluated in combination with Merck's Keytruda in an ongoing Phase 3 trial. Additionally, J&J extended its contract with Trellus Health for patient support services through mid-2026.

02/18/2026, 10:10 AM • Benzinga

Clinical Trials Support Software Solutions in a $34.15B Trial Economy by 2035

The global clinical trials support software solutions market is valued at USD 14.31 billion in 2026 and is expected to reach USD 34.15 billion by 2035, growing at a 10.15% CAGR. North America leads the market while Asia Pacific shows the fastest growth. CTMS solutions dominate by product type, cloud-based delivery leads, and CROs lead by end-user segment. Key growth drivers include increasing clinical trial complexity, adoption of decentralized trials, AI-driven analytics, and regulatory compliance demands.

02/18/2026, 10:00 AM • GlobeNewswire

GEMI ALERT: Gemini Space Station Shareholders Should Contact Block & Leviton To Potentially Recover Losses

Block & Leviton is investigating Gemini Space Station, Inc. (GEMI) for potential securities law violations after the company's stock fell over 10% following the sudden departure of multiple senior executives including its COO, CFO, and Chief Legal Officer. This leadership shakeup occurred months after the company's September 2025 IPO at $28 per share and follows a previously announced 25% workforce reduction plan.

02/17/2026, 2:30 PM • GlobeNewswire

Clinical Research Provider Icon Stock Crashes On Accounting Probe

Icon Plc (NASDAQ: ICLR) shares plummeted 32.55% in premarket trading after disclosing an internal accounting investigation by its Audit Committee. The probe, which began in October 2025, focuses on revenue recognition practices from 2023-2025, with preliminary findings indicating revenue may have been overstated by less than 2% in each year. The company has withdrawn its 2025 guidance and delayed financial reporting, with results expected by April 30, 2026.

02/12/2026, 7:38 AM • Benzinga

Trinity Street Sells $22 Million of Axalta Coating Systems Stock

Trinity Street Asset Management completely exited its position in Axalta Coating Systems, selling 770,919 shares worth approximately $22.1 million. The exit represents a full liquidation of the fund's stake in the specialty coatings company. Trinity simultaneously increased its positions in higher-growth companies like Taiwan Semiconductor Manufacturing, suggesting the fund manager sees better growth prospects in the semiconductor and technology sectors compared to the slower-growing industrial coatings industry.

01/27/2026, 2:12 PM • The Motley Fool

Real World Evidence Solutions Research and Forecast Report 2025-2030: Growth Opportunities in Emerging Markets and Increased Focus on End-To-End Rwe Services, & Personalized and Precision Medicine

The global real world evidence (RWE) solutions market is projected to grow from $5.42 billion in 2025 to $10.83 billion by 2030, with a 14.8% CAGR, driven by value-based care, chronic disease prevalence, and advancements in healthcare data analytics.

10/01/2025, 10:00 AM • GlobeNewswire

ICON Stock Up After Q2 Results Signal Growing Confidence In Biopharma Recovery

Clinical research organization ICON reported better-than-expected Q2 financial results, with quarterly sales of $2.02 billion and adjusted earnings of $3.26 per share. The company raised its fiscal 2025 sales guidance and expanded its share buyback program to $1 billion.

07/24/2025, 2:01 PM • Benzinga